• Cybin has changed its legal name to Helus Pharma, rebranding its corporate identity around its serotonergic agonist drug-development platform.
• Shares will keep trading on Nasdaq Global Market, Cboe Canada under ticker HELP.
• Pipeline focus includes HLP003 in Phase 3 for major depressive disorder, HLP004 in Phase 2 for generalized anxiety disorder.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cybin Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010730PRIMZONEFULLFEED9837494) on October 01, 2026, and is solely responsible for the information contained therein.